Pharmacological inhibition of CCR9 is a novel approach in the treatment of inflammatory bowel disease

Παρόμοια τεκμήρια

• Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease.
  ανά: Walters, M, κ.ά.
  Έκδοση: (2010)
• Ccx282-B, an orally active inhibitor of chemokine receptor Ccr9, shows anti-inflammatory and clinical activity in the treatment of Crohn's disease
  ανά: Keshav, S, κ.ά.
  Έκδοση: (2007)
• Traficet-EN (CCX282-B), an orally active inhibitor of chemokine receptor CCR9, for treatment of Crohn's disease
  ανά: Bekker, P, κ.ά.
  Έκδοση: (2007)
• CCR9 antagonism: potential in the treatment of Inflammatory Bowel Disease.
  ανά: Wendt, E, κ.ά.
  Έκδοση: (2015)
• MEDI 167-Discovery of the highly potent, selective and orally bioavailable CCR9 antagonist CCX282-B
  ανά: Ungashe, S, κ.ά.
  Έκδοση: (2008)